Carbaglu (Carglumic Acid) Patent Expiration, LOE Window & CMS Spending

Carbaglu (Carglumic Acid) by Recordati Rare Diseases: FDA Orange Book LOE 2028-01-22, 2 AB generics, $36.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRecordati Rare Diseases
FDA Application & PathwayN022562 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-01-22
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$36.8M
2024 Medicare Part D Spend$10.8M
2024 Medicaid Spend$25.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel